Now Reading: Aurobindo’s Lannett unit gets 4 US FDA observations in Indiana plant inspection
-
01
Aurobindo’s Lannett unit gets 4 US FDA observations in Indiana plant inspection
Aurobindo’s Lannett unit gets 4 US FDA observations in Indiana plant inspection
The US Food and Drug Administration (FDA) has issued four observations to Lannett Company LLC, the US subsidiary of Aurobindo Pharma, after inspecting its manufacturing facility in Seymour, Indiana from August 17…
The US Food and Drug Administration (FDA) has issued four observations to Lannett Company LLC, the US subsidiary of Aurobindo Pharma, after inspecting its manufacturing facility in Seymour, Indiana from August 17 to 21. Aurobindo described the observations as procedural in nature and said it has responded within the stipulated timeline, reaffirming its commitment to quality standards.
Aurobindo Pharma completed its $250 million acquisition of Pennsylvania-based Lannett in June 2024, gaining the company's portfolio of complex, non-opioid controlled substances. The Seymour facility has the capacity to produce approximately 4 billion doses annually.
The FDA's inspection outcome follows the company's recent regulatory milestone with the US Federal Trade Commission approving the acquisition. Aurobindo now awaits the agency's final review of the observations.
Indian Opinion Analysis
This is the first FDA inspection at Lannett's Seymour plant since Aurobindo completed its $250 million acquisition in June 2024. The four procedural observations are relatively low in number, a typical US FDA inspection can yield zero to more than a dozen Form 483 observations. For Aurobindo, which has faced FDA scrutiny at several Indian facilities over the years, the outcome matters because Lannett's non-opioid controlled substances portfolio is central to its US growth strategy. The 4 billion-dose capacity makes Seymour a key asset. Aurobindo now waits for the FDA's post-inspection review, which will determine whether the observations escalate into a warning letter or are closed as minor procedural issues. The next signal is the FDA's close-out letter, typically issued within a few weeks.
Source: thehindu.com
This brief was synthesised by AI from the source linked above.
